The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1402
October 29, 2012
View Complete Issue         Table of Contents 2019 
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
October 29, 2012 (Issue: 1402)
The FDA has approved a nasal spray fixed-dose combination (Dymista – Meda) of the H1-antihistamine azelastine (Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate (Flonase, and generics) for treatment of seasonal allergic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Azelastine/Fluticasone Propionate (Dymista) for Seasonal Allergic Rhinitis
Article code: 1402a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.